Q6ZQ58
PR
Gene name |
Larp1 (Kiaa0731, Larp) |
Protein name |
La-related protein 1 |
Names |
La ribonucleoprotein domain family member 1 |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:73158 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q6ZQ58
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q6ZQ58-F1 | Predicted | AlphaFoldDB |
62 variants for Q6ZQ58
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs579242451 | 78 | P>L | No | EVA | |
| rs3389162148 | 146 | A>T | No | EVA | |
| rs249698614 | 147 | V>I | No | EVA | |
| rs3389130798 | 211 | C>Y | No | EVA | |
| rs3389152356 | 229 | Q>* | No | EVA | |
| rs3389152316 | 242 | A>V | No | EVA | |
| rs50250532 | 257 | V>I | No | EVA | |
| rs3389132462 | 281 | W>* | No | EVA | |
| rs3389156848 | 283 | P>Q | No | EVA | |
| rs3389154273 | 286 | K>Q | No | EVA | |
| rs3389157783 | 289 | P>L | No | EVA | |
| rs3389123514 | 316 | G>E | No | EVA | |
| rs3389123589 | 337 | Q>* | No | EVA | |
| rs3389170593 | 362 | F>I | No | EVA | |
| rs3413085442 | 392 | V>M | No | EVA | |
| rs3412802937 | 408 | D>E | No | EVA | |
| rs3389164553 | 472 | D>G | No | EVA | |
| rs3389170656 | 477 | L>F | No | EVA | |
| rs3402418643 | 485 | R>P | No | EVA | |
| rs3389170655 | 488 | Y>H | No | EVA | |
| rs3389158163 | 503 | T>I | No | EVA | |
| rs3389158003 | 511 | E>K | No | EVA | |
| rs3389154275 | 524 | A>T | No | EVA | |
| rs3389154303 | 535 | I>F | No | EVA | |
| rs3389157976 | 581 | E>V | No | EVA | |
| rs3389152349 | 598 | N>S | No | EVA | |
| rs3389096458 | 610 | Y>F | No | EVA | |
| rs3389157803 | 645 | R>C | No | EVA | |
| rs3389096416 | 653 | A>G | No | EVA | |
| rs3389158224 | 668 | W>R | No | EVA | |
| rs3389159051 | 674 | P>S | No | EVA | |
| rs3389134390 | 682 | E>K | No | EVA | |
| rs3389123551 | 710 | Q>H | No | EVA | |
| rs3389134420 | 712 | V>I | No | EVA | |
| rs3389157793 | 717 | P>H | No | EVA | |
| rs3402546665 | 720 | Q>EEPPG* | No | EVA | |
| rs3389123560 | 725 | D>N | No | EVA | |
| rs3402351184 | 727 | L>M | No | EVA | |
| rs3389134445 | 753 | N>H | No | EVA | |
| rs3389157997 | 755 | R>L | No | EVA | |
| rs3389158056 | 758 | R>M | No | EVA | |
| rs3412825763 | 758 | R>S | No | EVA | |
| rs3389158022 | 760 | P>H | No | EVA | |
| rs3389146032 | 779 | P>S | No | EVA | |
| rs223001543 | 802 | N>K | No | EVA | |
| rs3389152333 | 828 | S>N | No | EVA | |
| rs26966452 | 871 | R>W | No | EVA | |
| rs3389164475 | 876 | N>S | No | EVA | |
| rs3389154269 | 883 | I>F | No | EVA | |
| rs3389130774 | 896 | W>L | No | EVA | |
| rs3389157844 | 900 | L>P | No | EVA | |
| rs3389096427 | 906 | K>T | No | EVA | |
| rs3389167866 | 907 | K>R | No | EVA | |
| rs3389158033 | 911 | E>V | No | EVA | |
| rs3389146042 | 913 | K>M | No | EVA | |
| rs3389167951 | 916 | A>T | No | EVA | |
| rs3389130808 | 917 | L>P | No | EVA | |
| rs3389162142 | 928 | L>* | No | EVA | |
| rs3389158185 | 970 | F>I | No | EVA | |
| rs3389152190 | 982 | L>V | No | EVA | |
| rs3389154290 | 1001 | F>L | No | EVA | |
| rs3389159042 | 1047 | T>M | No | EVA |
No associated diseases with Q6ZQ58
4 regional properties for Q6ZQ58
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| repeat | LARP1-like, DM15 repeat | 861 - 902 | IPR006607-1 |
| repeat | LARP1-like, DM15 repeat | 903 - 941 | IPR006607-2 |
| repeat | LARP1-like, DM15 repeat | 942 - 977 | IPR006607-3 |
| domain | La-type HTH domain | 372 - 462 | IPR006630 |
6 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| cytoplasmic stress granule | A dense aggregation in the cytosol composed of proteins and RNAs that appear when the cell is under stress. |
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| polysomal ribosome | A ribosome bound to mRNA that forms part of a polysome. |
| polysome | A multiribosomal structure representing a linear array of ribosomes held together by messenger RNA. They represent the active complexes in cellular protein synthesis and are able to incorporate amino acids into polypeptides both in vivo and in vitro. |
| TORC1 complex | A protein complex that contains at least TOR (target of rapamycin) and Raptor (regulatory-associated protein of TOR), or orthologs of, in complex with other signaling components. Mediates the phosphorylation and activation of S6K. In Saccharomyces, the complex contains Kog1p, Lst8p, Tco89p, and either Tor1p or Tor2p. |
9 GO annotations of molecular function
| Name | Definition |
|---|---|
| eukaryotic initiation factor 4E binding | Binding to eukaryotic initiation factor 4E, a polypeptide factor involved in the initiation of ribosome-mediated translation. |
| mRNA 3'-UTR binding | Binding to a 3' untranslated region of an mRNA molecule. |
| mRNA 5'-UTR binding | Binding to an mRNA molecule at its 5' untranslated region. |
| ribosomal small subunit binding | Binding to a small ribosomal subunit. |
| RNA 7-methylguanosine cap binding | Binding to a 7-methylguanosine group added cotranscriptionally to the 5' end of RNA molecules transcribed by polymerase II. |
| RNA binding | Binding to an RNA molecule or a portion thereof. |
| RNA cap binding | Binding to a 7-methylguanosine (m7G) group or derivative located at the 5' end of an RNA molecule. |
| translation activator activity | Any of a group of soluble proteins functioning in the activation of ribosome-mediated translation of mRNA into a polypeptide. |
| translation initiation factor binding | Binding to a translation initiation factor, any polypeptide factor involved in the initiation of ribosome-mediated translation. |
14 GO annotations of biological process
| Name | Definition |
|---|---|
| cell population proliferation | The multiplication or reproduction of cells, resulting in the expansion of a cell population. |
| cellular response to rapamycin | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a rapamycin stimulus. |
| mRNA stabilization | Prevention of degradation of mRNA molecules. In the absence of compensating changes in other processes, the slowing of mRNA degradation can result in an overall increase in the population of active mRNA molecules. |
| negative regulation of translation | Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA or circRNA. |
| negative regulation of translational initiation | Any process that stops, prevents, or reduces the frequency, rate or extent of translational initiation. |
| positive regulation of macroautophagy | Any process, such as recognition of nutrient depletion, that activates or increases the rate of macroautophagy to bring cytosolic macromolecules to the vacuole/lysosome for degradation. |
| positive regulation of translation | Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA or circRNA. |
| positive regulation of translational initiation | Any process that activates or increases the frequency, rate or extent of translational initiation. |
| positive regulation of viral genome replication | Any process that activates or increases the frequency, rate or extent of viral genome replication. |
| post-transcriptional regulation of gene expression | Any process that modulates the frequency, rate or extent of gene expression after the production of an RNA transcript. |
| response to amino acid starvation | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of amino acids. |
| TOR signaling | The series of molecular signals mediated by TOR (Target of rapamycin) proteins, members of the phosphoinositide (PI) 3-kinase related kinase (PIKK) family that act as serine/threonine kinases in response to nutrient availability or growth factors. |
| TORC1 signaling | A series of intracellular molecular signals mediated by TORC1; TOR (target of rapamycin) in complex with at least Raptor (regulatory-associated protein of TOR), or orthologs of, and other signaling components. |
| translational initiation | The process preceding formation of the peptide bond between the first two amino acids of a protein. This includes the formation of a complex of the ribosome, mRNA or circRNA, and an initiation complex that contains the first aminoacyl-tRNA. |
4 homologous proteins in AiPD
| 10 | 20 | 30 | 40 | 50 | 60 |
| MATQVEPLLP | AGAPLLQAEE | HGLARKKPAP | DAQAESGPGD | GGGEPDGGVR | RPRPACARPG |
| 70 | 80 | 90 | 100 | 110 | 120 |
| RDGAERESPR | PPAAAEAPAG | SDGEDGGRRD | FVEAPPPKVN | PWTKHAPPPA | AVNGQPPPEP |
| 130 | 140 | 150 | 160 | 170 | 180 |
| SAPAKVVRAA | APKPRKGSKV | GDFGDAVNWP | TPGEIAHKSV | QPQSHKPQPA | RKLPPKKDMK |
| 190 | 200 | 210 | 220 | 230 | 240 |
| EQEKGDGSDS | KESPKTKSDE | SGEEKNGDED | CQRGGQKKKG | SKHKWVPLQI | DMKPEVPREK |
| 250 | 260 | 270 | 280 | 290 | 300 |
| LASRPTRPQE | PRHTPAVRGE | MKGSEPATYM | PVSVAPPTPA | WQPETKVEPA | WHDQDETSSV |
| 310 | 320 | 330 | 340 | 350 | 360 |
| KSDGAGGARA | SFRGRGRGRG | RGRGRGRGGT | RTHFDYQFGY | RKFDGTEGPR | THKYMNNITY |
| 370 | 380 | 390 | 400 | 410 | 420 |
| YFDNVSSNEI | YSMDQELLKD | YIKRQIEYYF | SVDNLERDFF | LRRKMDADGF | LPITLIASFH |
| 430 | 440 | 450 | 460 | 470 | 480 |
| RVQALTTDIS | LIFAALKDSK | VVEMVEEKVR | RREEPEKWPL | PGPPIVDYSQ | TDFSQLLNCP |
| 490 | 500 | 510 | 520 | 530 | 540 |
| EFVPRQHYQK | ETESAPGSPR | AVTPVPTKTE | EVSNLKTLPK | GLSASLPDLD | SESWIEVKKR |
| 550 | 560 | 570 | 580 | 590 | 600 |
| PRPSPARPKK | PEEPRFSHPT | ALPQQLPSQQ | LMSKDQDEQE | ELDFLFDEEM | EQMDGRKNTF |
| 610 | 620 | 630 | 640 | 650 | 660 |
| TAWSEEDSDY | EIDDRDVNKI | LIVTQTPPYM | RRHPGGDRTG | NHTSRAKMSA | ELAKVINDGL |
| 670 | 680 | 690 | 700 | 710 | 720 |
| FYYEQDLWTE | KFEPEYSQIK | QEVENFKKVN | MISREQFDTL | TPEPPVDPNQ | EVPPGPPRFQ |
| 730 | 740 | 750 | 760 | 770 | 780 |
| QVPTDALANK | LFGAPEPSTI | ARSLPTTVPE | SPNYRNARTP | RTPRTPQLKD | SSQTPRFYPV |
| 790 | 800 | 810 | 820 | 830 | 840 |
| VKEGRTLDAK | MPRKRKTRHS | SNPPLESHVG | WVMDSREHRP | RTASISSSPS | EGTPAVGSYG |
| 850 | 860 | 870 | 880 | 890 | 900 |
| CTPQSLPKFQ | HPSHELLKEN | GFTQHVYHKY | RRRCLNERKR | LGIGQSQEMN | TLFRFWSFFL |
| 910 | 920 | 930 | 940 | 950 | 960 |
| RDHFNKKMYE | EFKQLALEDA | KEGYRYGLEC | LFRYYSYGLE | KKFRLDIFKD | FQEETVKDYE |
| 970 | 980 | 990 | 1000 | 1010 | 1020 |
| AGQLYGLEKF | WAFLKYSKAK | NLDIDPKLQE | YLGKFRRLED | FRVDPPMGEE | GNHKRHPVVA |
| 1030 | 1040 | 1050 | 1060 | 1070 | |
| GGSGEGRKRC | PSQSSSRPAT | GISQPPTTPT | GQATREDAKW | TSQHSDTLTL | RK |